Orthofix Medical (NASDAQ:OFIX) and Viatar CTC Solutions (OTCMKTS:VRTT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Earnings & Valuation

This table compares Orthofix Medical and Viatar CTC Solutions’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orthofix Medical $453.04 million 2.20 $13.81 million $1.96 26.64
Viatar CTC Solutions N/A N/A N/A N/A N/A

Orthofix Medical has higher revenue and earnings than Viatar CTC Solutions.

Insider & Institutional Ownership

94.4% of Orthofix Medical shares are owned by institutional investors. 5.6% of Orthofix Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Orthofix Medical and Viatar CTC Solutions, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orthofix Medical 0 1 1 0 2.50
Viatar CTC Solutions 0 0 0 0 N/A

Orthofix Medical currently has a consensus price target of $60.00, suggesting a potential upside of 14.92%. Given Orthofix Medical’s higher possible upside, equities research analysts clearly believe Orthofix Medical is more favorable than Viatar CTC Solutions.


This table compares Orthofix Medical and Viatar CTC Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Orthofix Medical 2.09% 10.45% 7.52%
Viatar CTC Solutions N/A N/A N/A

Volatility & Risk

Orthofix Medical has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Viatar CTC Solutions has a beta of -0.79, suggesting that its share price is 179% less volatile than the S&P 500.


Orthofix Medical beats Viatar CTC Solutions on 9 of the 9 factors compared between the two stocks.

About Orthofix Medical

Orthofix Medical Inc., a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through four segments: Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. The Bone Growth Therapies segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spinal appendicular fractures. The Spinal Implants segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Orthofix Extremities segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.

About Viatar CTC Solutions

Viatar CTC Solutions Inc., a biotechnology company, focuses on developing and marketing cancer molecular diagnostics and cancer therapy products in the United States. Its products include Viatar collection system for molecular analysis that collects and purifies circulating tumor cells (CTCs) for DNA sequencing and other genetic analysis technologies used primarily for research; and Viatar therapeutic oncopheresis system to remove CTCs from a patient's blood as a new cancer therapy for metastatic disease. The company was formerly known as Vizio Medical Devices LLC and changed its name to Viatar CTC Solutions Inc. in February 2014. Viatar CTC Solutions Inc. was founded in 2007 and is headquartered in Lowell, Massachusetts.

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.